SCHEMBL4858634

SCHEMBL4858634

CC(C)c1ccc(N=C(N)c2ccncc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
GRIN2D O15399 1/20 0.49
GRIN3B O60391 1/20 0.49
GRIN1 Q05586 1/20 0.49
GRIN2A Q12879 1/20 0.49
GRIN2B Q13224 1/20 0.49
GRIN2C Q14957 1/20 0.49
GRIN3A Q8TCU5 1/20 0.49
SIGMAR1 Q99720 1/20 0.49
NOS3 P29474 5/20 0.47
NOS1 P29475 5/20 0.47
NOS2 P35228 4/20 0.47
PRSS1 P07477 1/20 0.44
ACR P10323 1/20 0.44
PLG P00747 1/20 0.44
SCN5A Q14524 1/20 0.43
SCN2A Q99250 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4861785 0.81 CYP2D6 (0.62) ALDH1A1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL4861629 0.78 NOS3 (0.54) ALDH1A1SMN1; SMN2GRIN2DGRIN3BGRIN1
SCHEMBL4854784 0.77 SLC22A2 (0.53) ALDH1A1NOS3NOS1NOS2PLG
SCHEMBL4858663 0.75 PRSS1 (0.47) ALDH1A1SMN1; SMN2GRIN2DGRIN3BGRIN1
SCHEMBL5594422 0.74 MAPT (0.46) ALDH1A1SMN1; SMN2GRIN2BNOS3NOS1
SCHEMBL23411272 0.74 PLG (0.53) ALDH1A1SMN1; SMN2GRIN2BNOS3NOS1
SCHEMBL4857024 0.73 ADRA2A (0.61) ALDH1A1SMN1; SMN2PRSS1SCN2AKMT2A
SCHEMBL834376 0.69 PLG (0.50) ALDH1A1SMN1; SMN2PLGMEN1KMT2A
SCHEMBL12900245 0.69 HTT (0.57) ALDH1A1SMN1; SMN2GRIN2DGRIN3BGRIN1
SCHEMBL1505344 0.69 HTT (0.57) ALDH1A1SMN1; SMN2GRIN2DGRIN3BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365069-B2 Pyrimidone derivatives BEXEL PHARMACEUTICALS INC. (US) 2008-04-29 US disclosed
US-20040259891-A1 Novel pyrimidon derivatives ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259891-A1 Novel pyrimidon derivatives TYMS, TPMT, TYMP ALDH1A1 272/4885SMN1; SMN2 2461/4885GRIN2D 896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.